Deal Tracker · Countries

Switzerland pharma deals

18 pharma deals involving Switzerland — companies based there or deals covering the market — tracked by EPT: licensing, M&A & distribution. Most active: Sandoz, Roche, Department of Health – Abu Dhabi & DKSH. Latest: Santhera Pharmaceuticals → SteinCares (Distribution, 12 Nov 2026).

18
deals tracked
17
announced in 2026
$402m
disclosed value (2 deals)
22%
licensing, the top deal type
  • EPT has tracked 18 Switzerland pharma deals (2025–2026), 17 of them announced in 2026.
  • The most common structures are licensing (22%), m&a (22%) & distribution (17%).
  • Values were disclosed for 2 of 18 deals, totalling $402m; the largest is DKSH → NewBridge Pharmaceuticals ($390m, 19 Oct 2026).
  • The most active companies: Sandoz (4), Roche (3), Department of Health – Abu Dhabi (2) & DKSH (2).

Most active companies

Sandoz (4) · Roche (3) · Department of Health – Abu Dhabi (2) · DKSH (2)

Countries involved

Saudi Arabia (4) · UAE (4) · Argentina (3) · Brazil (3) · Algeria (2) · Egypt (2)

Largest disclosed deals

Questions

How many Switzerland pharma deals has EPT tracked?
18 as of 12 Nov 2026, covering 2025–2026; 17 were announced in 2026. The most recent is Santhera Pharmaceuticals → SteinCares (Distribution, 12 Nov 2026).
What types of Switzerland pharma deals are most common?
Licensing: 4 (22%); M&A / Acquisition: 4 (22%); Distribution: 3 (17%); Partnership / Collaboration: 3 (17%).
Which companies are most active in Switzerland pharma deals?
Sandoz (4 deals), Roche (3 deals), Department of Health – Abu Dhabi (2 deals), DKSH (2 deals).
What is the largest disclosed Switzerland pharma deal?
DKSH → NewBridge Pharmaceuticals: $390m (M&A / Acquisition, 19 Oct 2026); Sandoz → Strides Pharma: $12m (M&A / Acquisition, 17 Mar 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)